* Cosmos Health Inc is expected to report resultson April 11 (estimated) for the period ending December 31 2023
* The Chicago Illinois-based company is expected to report revenue of $13.75 million, according to the estimate from one analyst, based on LSEG data.
* LSEG's mean analyst estimate for Cosmos Health Inc is for a loss of 20 cents per share.
* The one available analyst rating on the shares is "buy".
* The average consensus recommendation for the pharmaceuticals peer group is also "Buy".
* Wall Street's median 12-month price target for Cosmos Health Inc is $4.00, above its last closing price of $0.70.
This summary was machine generated April 9 at 20:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments